This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): R4996, MEM 63908
Description: MEM 63908 is a partial agonist of the nicotinic alpha-7 receptor. Alpha-7 nicotinic acetylcholine receptors are thought to be involved in memory, cognition, synaptic plasticity, and neuronal survival. They not only mediate cholinergic transmission but also influence signaling at noncholinergic synapses (such as glutamate and serotonin). In addition, they may mediate dopamine release in response to nicotine, particularly in the nucleus accumbens, part of the classic reward pathway.
Deal Structure: In August 2003, Memory entered into a collaboration with Roche to develop nicotinic alpha-7 agonists, which included an upfront payment and research funding. In February 2006, the Company amended this agreement to expand the resources dedicated to the discovery and development of nicotinic alpha-7 agonists for the prevention and treatment of diseases, in all indications, for either human or veterinary use. Under the expanded agreement, the Company has granted Roche an exclusive worldwide license to their intellectual property on nicotinic alpha-7 receptor compounds. Under the new agreement, both companies will actively collaborate on the discovery and clinical development of nicotinic alpha-7 agonists. Memory will conduct Phase I clinical trials for compounds that emerge from the collaboration, and Roche will assume responsibility for later-stage development and commercialization. Under the terms of the amended agreement, Roche is also obligated to make milestone payments to Memory...See full deal structure in Biomedtracker
Additional information available to subscribers only: